Fosun Pharma subsidiary's chronic constipation drug application accepted

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma") announced that the drug registration application for Polyethylene Glycol (3350) Electrolytes Powder, submitted by its subsidiary, Shanghai Zhaohui Pharmaceutical Company Limited, has been accepted by the National Medical Products Administration. This chemical drug is intended for treating chronic constipation, excluding cases caused by organic diseases.

As of October 2025, the Fosun Group has invested approximately RMB6.21 million in the research and development of the Polyethylene Glycol Electrolytes Powder series drugs, including the recently accepted drug. According to IQVIA CHPA data, sales of Polyethylene Glycol Electrolytes Powder in China (excluding Hong Kong, Macao, and Taiwan regions) reached approximately RMB873 million in 2024.

Fosun Pharma cautioned that the drug's commercial production is contingent upon obtaining final drug registration approval. The company also highlighted the inherent uncertainties in the pharmaceutical industry regarding future sales performance, which can be influenced by factors such as medication demand, market competition, and sales channels. At this stage, the acceptance of the drug registration application is not expected to have a material impact on the group's results.